Document RjxxDgK5JjOmN9pYen27bkgYa

To: From: Cc: Bcc: Received Date: Subject: Clegg, Patsy M SCC-DCS/22 <patsy.clegg@shell.com> brian.e.doll@exxonmobil.com <brian.e.doll@exxonmobil.com> 2007-05-1712:42:52 GMT Fw: Shanghai Health Study - Cinpathogen Milestones -- wi att. Patsy, As we discussed, attached FYI are the two May 11 letters from Cinpathogen responding to the BHRC milestones sent on May 7 via the attached email (so you will have the two sets in one place). The originals sent Friday could apparently not make it through our fire wall. Regards, Brian (See attached file: Cinpathogen Response to May 7 milestones.pdf)(See attached file: Cinpathogen Regulatory issues RE modified deliverables.pdf) ----- Forwarded by Brian E DoIl/FairfaX/Mobil-Notes on 05115/07 08:50 AM "Howard Feldman" <Feldman@api.o To rg> <richard.irons@cinpathogen.com> cc <BenzConsort-OC@listserve.api.org>, 05/07/0711 :39 <BenzConsort-TC@listserve.api.org>, AM "Brenda Hargett" <Hargettb@api.org>, "Bob Greco" <Greco@api.org>, "Harry Ng" <Ng@api.org> Subject Shanghai Health Study - Cinpathogen Milestones Dr. Irons, The Benzene Health Research Consortium has revised the milestone reporting request as described in the attached document. The milestones set forth herein are to allow API and the Oversight Committee to fulfill their obligations to monitor costs and the progress of the study. Please contact me if you have any questions. Howard Feldman SH ELL-MCCLU RG-062092